Drug intelligence / Profile preview

cord blood-natural killer cells

Development stage
Phase 1
Lead developer
University of Texas MD Anderson Cancer Center
Modality
CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration
Intravenous
01

Overview

Cord blood-natural killer cells are immune effector cells isolated and expanded from human umbilical cord blood for use in adoptive cell therapy, particularly for cancer. These cells are a form of allogeneic NK (natural killer) cells that can recognize and destroy tumor cells independently of prior sensitization or MHC restriction. They have been investigated as “off-the-shelf” cell therapy products that do not require donor-patient HLA matching, and are used in both native and genetically engineered forms (such as CAR-NK). Their main mechanism is exerting cytotoxicity against malignant cells through natural cytotoxicity receptors and the release of perforin and granzymes. Cord blood NK cells are being tested in a range of solid and hematologic malignancies, and clinical trials have reported promising antitumor effects with low toxicity and minimal graft-versus-host disease. Ex vivo expansion is often used to increase cell yield and function prior to infusion. Developers include academic research groups and biotechnology companies[1][3][5][2][9].

Other names
cord blood-derived natural killer cellsCB-NK cellsumbilical cord blood natural killer cellsUCB-derived NK cells
02

Targets

NCR3LG1 (Natural cytotoxicity triggering receptor 3 ligand 1)MICB (Major histocompatibility complex class i-related protein B)

Beyond the preview

Go deeper on cord blood-natural killer cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cord blood-natural killer cells.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call